One key feature of our model is that a luminal-like subtype can be induced from the basal subtype of urothelial carcinoma by pharmacological modulation with 5’-azacitidine, to increase the expression of Shh in tumor cells, resulting in an increased stromal Hh response. The gene discussed is SHH; the disease is urothelial carcinoma.